Goldstein Sarah A, Ward Cary C, Al-Khatib Sana M
Division of Cardiology, Duke University Hospital, Durham, NC, USA.
Duke Clinical Research Institute, Duke University Hospital, Durham, NC, USA.
J Innov Card Rhythm Manag. 2018 Jan 15;9(1):2996-3005. doi: 10.19102/icrm.2018.090103. eCollection 2018 Jan.
Some congenital heart diseases (CHDs) and inherited arrhythmia syndromes are associated with an increased risk of sudden cardiac death (SCD). Appropriate selection criteria for implantable cardioverter-defibrillator (ICD) implantation in these patients are poorly defined due to a paucity of data available from randomized clinical trials, leading to current guidelines relying more on non-randomized studies and expert opinions to make their recommendations. This review describes available evidence-based risk stratification methods for identifying patients at risk for SCD, as well as current guideline-driven management strategies for the use of ICDs in patients with CHD and inherited arrhythmia syndromes.
一些先天性心脏病（CHD）和遗传性心律失常综合征与心源性猝死（SCD）风险增加相关。由于缺乏来自随机临床试验的数据，这些患者植入式心律转复除颤器（ICD）植入的合适选择标准定义不清，导致当前指南更多地依赖非随机研究和专家意见来提出建议。本综述描述了用于识别SCD风险患者的现有循证风险分层方法，以及当前指南驱动的CHD和遗传性心律失常综合征患者使用ICD的管理策略。
